Carbidopa
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Carbidopa |
| DrugBank ID | DB00190 |
| Brand Names (EU) | Carbidopa |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.27% |
Approved Indication (EMA)
Stalevo is indicated for the treatment of adult patients with Parkinson’s disease and end-of-dose motor fluctuations not stabilised on levodopa / dopa-decarboxylase (DDC)-inhibitor treatment.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | hereditary late onset Parkinson disease | 99.27% | DL |
| 2 | X-linked parkinsonism-spasticity syndrome | 98.83% | DL |
| 3 | juvenile onset Parkinson disease 19A | 98.51% | DL |
| 4 | Rasmussen subacute encephalitis | 98.43% | DL |
| 5 | PLA2G6-associated neurodegeneration | 97.60% | DL |
| 6 | atypical juvenile parkinsonism | 97.45% | DL |
| 7 | transaldolase deficiency | 97.40% | DL |
| 8 | hemiparkinsonism-hemiatrophy syndrome | 97.40% | DL |
| 9 | myelitis | 97.40% | DL |
| 10 | fructose-1,6-bisphosphatase deficiency | 97.09% | DL |
| 11 | parkinsonian-pyramidal syndrome | 96.01% | DL |
| 12 | Lewy body dementia | 95.99% | DL |
| 13 | paralysis agitans, juvenile, of Hunt | 95.60% | DL |
| 14 | Parkinson disease | 95.56% | DL |
| 15 | progressive supranuclear palsy-corticobasal syndrome | 95.36% | DL |
| 16 | early-onset parkinsonism-intellectual disability syndrome | 95.17% | DL |
| 17 | X-linked intellectual disability-ataxia-apraxia syndrome | 94.87% | DL |
| 18 | X-linked intellectual disability-cerebellar hypoplasia syndrome | 93.72% | DL |
| 19 | multiple system atrophy, parkinsonian type | 93.46% | DL |
| 20 | CLCN4-related X-linked intellectual disability syndrome | 93.18% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.